About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
The Biosimilar Red Tape Elimination Act would deem all biosimilars interchangeable with their reference products without the U.S. Food and Drug Administration (FDA) needing to make any additional determination. The bill would do away with important scientific standards while failing to address the broader misaligned incentives in the marketplace allowing pharmacy benefit managers (PBMs) to block biosimilar competition and profit off medicines at the expense of patients.
The Biosimilar Red Tape Elimination Act Provides a New Profit Source for PBMs image
Fact Sheet
Medicaid
The Biosimilar Red Tape Elimination Act Provides a New Profit Source for PBMs
The Biosimilar Red Tape Elimination Act Provides a New Profit Source for PBMs image